COLUMBIA, Md., Sept. 10 /PRNewswire/ -- Cylex, Inc., a venture-backed global life sciences company that develops and manufactures research and in vitro diagnostic products intended to illuminate immunity, announced today the appointment of the company's president, Brad L. Stewart, to chief executive officer and chairman of the board. Since joining Cylex as president in December 2007, Mr. Stewart has successfully led the development of the company's commercial infrastructure, expansion internationally to 18 countries and substantial revenue growth.
"The expanded commercialization of Cylex's technology presents an exciting opportunity for the company to develop cellular diagnostics for diseases and treatments where the immune system is affected," said President, CEO and Chairman Brad L. Stewart. "We have already seen significantly growing demand for our lead product, ImmuKnow(R), and are very excited to explore new and better ways Cylex will be able to positively contribute to patient care in the future."
"Brad has demonstrated strong leadership since joining Cylex and has built an impressive management team. We are confident in his ability to continue to drive commercial growth as a global leader in cellular diagnostics and to deliver substantial shareholder value," said Greg Shearer, founder and principal of Channel Medical Partners.
"Brad has shown his flair for commercial strategy and execution. As a result, the Cylex Board of Directors voted unanimously to appoint Brad to his new role," said Stephen Bloch, MD, a Cylex director and general partner with Canaan Partners.
ImmuKnow is increasingly being adopted at organ transplant centers throughout the United Sta
|SOURCE Cylex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved